Position in JANX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$1,610,551
+$853,518 QoQ
Shares Held
115,867
+253.6% QoQ
Ownership
0.190%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CAPITAL FUND MANAGEMENT S.A. holds $292,594,996 across 34 Biotechnology names. JANX ranks #24 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
122,934 | $54,894,948 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
140,109 | $46,357,864 | |
| 3 | INCY |
Incyte Corp
|
312,021 | $29,367,416 | |
| 4 | MRNA |
Moderna, Inc.
|
569,930 | $28,952,444 | |
| 5 | EXEL |
Exelixis, Inc.
|
479,693 | $20,574,032 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
174,378 | $11,270,050 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
142,201 | $10,677,873 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
181,065 | $10,228,361 |
All Filings in JANX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,610,551 | 115,867 | Shares | Sole | 2026-05-14 | |
| 2025-06-30 | $757,033 | 32,772 | Shares | Sole | 2025-08-13 | |
| 2024-09-30 | $676,361 | 14,888 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||